It was announced at the JPMorgan Healthcare Conference (7–10 January, San Francisco, USA) that SpinalCyte has been issued a new Australian patent related to its fibroblast technology. The company’s portfolio in spine treatments now includes 36 US and foreign patents with 40 pending.
The technologies described in Australian patent No. 2017206234, “Methods And Compositions For Repair Of Cartilage Using An In Vivo Bioreactor”, are related to differentiating HDF’s into chondrocyte-like cells by exposing them to a specific environment of growth factors, hypoxia, hydrostatic pressure and shear stress.
The US Food and Drug Administration (FDA) recently cleared the company’s Investigational New Drug protocol and results from its Phase 1/Phase 2 clinical trial were positive. The company hope to continue development and clinical trials into the effectiveness of its fibroblast cell technology.
CybroCell is the first off-the-shelf allogenic human dermal fibroblast (HDF) product for the treatment of degenerative disc disease. SpinalCyte’s Phase 1/Phase 2 clinical trial for injected human dermal fibroblasts in the treatment of DDD demonstrated after 12 months, patients experienced sustained improvement in pain relief and increased back mobility.